Karyopharm Therapeutics Files Q3 2024 10-Q

TL;DR

KPTI Q3 10-Q filed. Financials and key agreements updated.

AI Summary

Karyopharm Therapeutics Inc. filed its 10-Q for the period ending September 30, 2024. The company reported on its financial performance, including details on its common stock and warrants. Key agreements mentioned include those with Antengene Therapeutics Limited and Menarini License Agreement, as well as an Amended Revenue Interest Agreement with Healthcare Royalty Partners IV LP.

Why It Matters

This filing provides investors with an update on Karyopharm's financial health and operational activities for the third quarter of 2024, impacting investment decisions.

Risk Assessment

Risk Level: medium — The company operates in the volatile pharmaceutical sector, and the filing details financial performance and agreements that carry inherent risks.

Key Numbers

• 2024-09-30 — Reporting Period End (Financials for this date are detailed in the 10-Q.)
• 2024-01-01 to 2024-09-30 — Year-to-Date Period (Covers the first nine months of 2024 for various financial activities.)
• 2023-01-01 to 2023-09-30 — Prior Year-to-Date Period (Provides comparative data for the first nine months of 2023.)

Key Players & Entities

• Karyopharm Therapeutics Inc. (company) — Filer
• September 30, 2024 (date) — Reporting period end date
• Antengene Therapeutics Limited (company) — Licensing partner
• Menarini License Agreement (company) — Licensing agreement
• Healthcare Royalty Partners IV LP (company) — Revenue interest agreement counterparty
• Jefferies LLC (company) — Underwriter for open market sale agreement

FAQ

Key Financial Figures

• $0.0001 — on which registered Common Stock , $0.0001 par value KPTI Nasdaq Global Select

Filing Documents

• kpti-20240930.htm (10-Q) — 2641KB
• kpti-ex31_1.htm (EX-31.1) — 11KB
• kpti-ex31_2.htm (EX-31.2) — 11KB
• kpti-ex32_1.htm (EX-32.1) — 7KB
• kpti-ex32_2.htm (EX-32.2) — 7KB
• 0000950170-24-121076.txt ( ) — 9384KB
• kpti-20240930.xsd (EX-101.SCH) — 1322KB
• kpti-20240930_htm.xml (XML) — 1462KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 2 Item 1. Condensed Consolidated Financial Statements (Unaudited) 2 Condensed Consolidated Balance Sheets 2 Condensed Consolidated Statements of Operations 3 Condensed Consolidated Statements of Comprehensive Income (Loss) 4 Condensed Consolidated Statements of Cash Flows 5 Condensed Consolidated Statements of Stockholders' Deficit 6 Notes to Condensed Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 20 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 28

- OTHER INFORMATION

PART II - OTHER INFORMATION 29 Item 1A.

Risk Factors

Risk Factors 29 Item 5. Other Information 77 Item 6. Exhibits 78

Signatures

Signatures 79 1 Table of Contents

- FINANCI AL INFORMATION

PART I - FINANCI AL INFORMATION

Condensed Consolid ated Financial Statements (Unaudited)

Item 1. Condensed Consolid ated Financial Statements (Unaudited). KARYOPHARM THERAPEUTICS INC. CONDENSED CONSOLIDAT ED BALANCE SHEETS (unaudited) (in thousands, except per share amounts) September 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 72,828 $ 52,231 Investments 60,698 139,212 Accounts receivable, net 31,778 26,962 Inventory 4,672 3,043 Prepaid expenses and other current assets 14,746 11,813 Restricted cash 33 660 Total current assets 184,755 233,921 Property and equipment, net 495 606 Operating lease right-of-use assets 2,586 4,276 Restricted cash 306 301 Other assets 1,334 1,334 Total assets $ 189,476 $ 240,438 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 5,783 $ 3,123 Accrued expenses 50,105 61,394 Operating lease liabilities 3,668 3,308 Other current liabilities 1,937 1,654 Total current liabilities 61,493 69,479 Convertible senior notes due 2025 24,392 170,919 Convertible senior notes due 2029 72,091 — Senior secured term loan 94,109 — Deferred royalty obligation 73,499 132,479 Common stock warrants 17,355 — Operating lease liabilities, net of current portion — 2,789 Other liabilities 6,184 978 Total liabilities 349,123 376,644 Stockholders' deficit: Preferred stock, $ 0.0001 par value; 5,000 shares authorized; none issued and outstanding — — Common stock, $ 0.0001 par value; 400,000 shares authorized; 125,303 and 114,915 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 13 12 Additional paid-in capital 1,373,242 1,350,981 Accumulated other comprehensive loss ( 222 ) ( 161 ) Accumulated deficit ( 1,532,680 ) ( 1,487,038 ) Total stockholders' deficit ( 159,647 ) ( 136,206 ) Total liabilities and stockholders' deficit $

View Full Filing

View this 10-Q filing on SEC EDGAR